Sophiris Bio Inc. (SPHS:NASDAQ) Investor Relations Material

Overview

Sophiris Bio Inc. is a biopharmaceutical company that is focused on late-stage clinical developments for urological diseases. The company is dedicated to the development of topsalysin, which is currently in Phase 2 clinical trials for the treatment of localized prostate cancer and Phase 3 clinical trials for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent, which is selective and targeted, and only activated by enzymatically active PSA found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells.

Frequently Asked Questions

What is Sophiris Bio Inc.'s ticker?

Sophiris Bio Inc.'s ticker is SPHS

What exchange is Sophiris Bio Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Sophiris Bio Inc.'s headquarters?

They are based in La Jolla, California

How many employees does Sophiris Bio Inc. have?

There are 1-10 employees working at Sophiris Bio Inc.

What is Sophiris Bio Inc.'s website?

It is http://www.sophirisbio.com/

What type of sector is Sophiris Bio Inc.?

Sophiris Bio Inc. is in the Healthcare sector

What type of industry is Sophiris Bio Inc.?

Sophiris Bio Inc. is in the Drugs - Generic industry

Who are Sophiris Bio Inc.'s peers and competitors?

The following five companies are Sophiris Bio Inc.'s industry peers:

- Akorn Inc.

- Flexion Therapeutics Inc

- Diplomat Pharmacy

- Catalent

- Mylan Nv